These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 26376010

  • 1. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution.
    Morgia G, Castelli T, Privitera S, Al-Nakib C, Favilla V, Marchese F, Cimino S, Russo GI.
    Aging Male; 2016; 19(1):15-9. PubMed ID: 26376010
    [Abstract] [Full Text] [Related]

  • 2. Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer.
    Ong WL, Hindson BR, Beaufort C, Pharoah P, Millar JL.
    Radiother Oncol; 2014 Jul; 112(1):72-6. PubMed ID: 25086852
    [Abstract] [Full Text] [Related]

  • 3. Erectile function after prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):437-47. PubMed ID: 15890585
    [Abstract] [Full Text] [Related]

  • 4. Erectile function after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH.
    Int J Radiat Oncol Biol Phys; 2002 Mar 15; 52(4):893-902. PubMed ID: 11958881
    [Abstract] [Full Text] [Related]

  • 5. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A, Wassermann J, Warszawski-Baumann A, Baumann R, Machtens S, Karstens JH, Christiansen H, Merseburger A, Kuczyk MA, von Klot C.
    BJU Int; 2013 May 15; 111(6):897-904. PubMed ID: 23305079
    [Abstract] [Full Text] [Related]

  • 6. Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with 125I low dose rate brachytherapy for localized prostate cancer.
    Chasseray M, Dissaux G, Bourbonne V, Boussion N, Goasduff G, Malloreau J, Malhaire JP, Fournier G, Tissot V, Pradier O, Valeri A, Schick U.
    Acta Oncol; 2019 Jul 15; 58(7):1029-1035. PubMed ID: 30761939
    [Abstract] [Full Text] [Related]

  • 7. Long-term potency preservation following brachytherapy for prostate cancer.
    Snyder KM, Stock RG, Buckstein M, Stone NN.
    BJU Int; 2012 Jul 15; 110(2):221-5. PubMed ID: 22734475
    [Abstract] [Full Text] [Related]

  • 8. Erectile function durability following permanent prostate brachytherapy.
    Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):639-48. PubMed ID: 19303721
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?
    Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):155-63. PubMed ID: 16111584
    [Abstract] [Full Text] [Related]

  • 10. The effect on erectile function of 103palladium implantation for localized prostate cancer.
    Ponholzer A, Oismüller R, Somay C, Büchler F, Maier U, Hawliczek R, Rauchenwald M, Madersbacher S.
    BJU Int; 2005 Apr 01; 95(6):847-50. PubMed ID: 15794796
    [Abstract] [Full Text] [Related]

  • 11. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer.
    Stock RG, Kao J, Stone NN.
    J Urol; 2001 Feb 01; 165(2):436-9. PubMed ID: 11176391
    [Abstract] [Full Text] [Related]

  • 12. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 01; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of Baseline Erectile Dysfunction (ED) in an Australian Cohort of Men with Localized Prostate Cancer.
    Ong WL, McLachlan H, Millar JL.
    J Sex Med; 2015 May 01; 12(5):1267-74. PubMed ID: 25847707
    [Abstract] [Full Text] [Related]

  • 14. Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.
    Rasmusson E, Gunnlaugsson A, Kjellén E, Nilsson P, Einarsdottir M, Wieslander E, Fransson P, Ahlgen G, Blom R.
    Acta Oncol; 2016 Aug 01; 55(8):1016-21. PubMed ID: 27174603
    [Abstract] [Full Text] [Related]

  • 15. Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy.
    Keyes M, Pickles T, Crook J, McKenzie M, Cheung A, Spadinger I, LaPointe V, Bachand WF, Morris J.
    Brachytherapy; 2015 Aug 01; 14(3):334-41. PubMed ID: 25684438
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M.
    J Urol; 2013 Mar 01; 189(3):1014-8. PubMed ID: 23017516
    [Abstract] [Full Text] [Related]

  • 18. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T, Taussky D, Donath D, Le HP, Larouche RX, Béliveau-Nadeau D, Hervieux Y, Delouya G.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e377-83. PubMed ID: 21514068
    [Abstract] [Full Text] [Related]

  • 19. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA, Fidaleo A, Pei X, Cohen G, Zaider M, Mo Q, Cox B, Yamada Y, Zelefsky MJ.
    BJU Int; 2013 Jun 15; 111(8):1231-6. PubMed ID: 23551568
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ, Keyes M, Palma D, McKenzie M, Spadinger I, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Lapointe V, Berthelet E, Pai H, Harrison R, Kwa W, Bucci J, Racz V, Woods R.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1432-8. PubMed ID: 19036530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.